

Indole, a Privileged Structural Core Motif

Isaac Giménez Sonsona

Laboratorio de Organocatálisis Asimétrica, Departamento de Química Orgánica, Instituto de Síntesis Química y Catálisis Homogénea (ISQCH), CSIC-Universidad de Zaragoza, C/ Pedro Cerbuna 12, E-50009 Zaragoza, Spain
sonsona@unizar.es

Published online: 14.08.2015

DOI: 10.1055/s-0034-1381172; Art ID: st-2015-v0526-v

Isaac Giménez Sonsona was born in Zaragoza, Spain, in 1991. He received his B.S. in chemistry at the University of Zaragoza in 2014. He is currently working towards his PhD degree in the Department of Organic Chemistry at the University of Zaragoza under the supervision of Dr. Raquel P. Herrera and Dr. Eugenia Marqués-López. His primary research interest focusses on the enantioselective organocatalytic study of different organic reactions aimed at the asymmetric synthesis of potential biologically active compounds.



Introduction

Indole (**1**), denominated by some authors as *The Lord of the Rings* of heterocyclic compounds¹ due to its importance in fields like chemistry, biology, and medicine,² represents the structural core of many natural and non-natural products with a wide range of biological properties, including antiviral³ and anticancer⁴ activities. An example of this spectrum of utilities is Arbidol (**2**), which is administered as a drug in Russia and China against influenza and other respiratory viral infections.⁵ Recent examples of other applications of indole-containing compounds are their potential use in SPECT imaging or detecting A β plaques in Alzheimer's disease, as compound **3**,⁶ or their use as ligands in the synthesis of organometallic complexes with optoelectronic properties and with potential use in the construction of light-emitting devices.⁷





Figure 1 Indole-based target compounds

Table 1 Use of Indole, a Privileged Structural Core Motif


(A) N1 Reactivity:

The total synthesis of the monoterpene alkaloid mersicarpine (**10**) was reported in 2014 by Liang's group.¹⁰ The synthesis involves the nucleophilic attack of the NH of the indole **7** to the activated carboxylic acid **8**, giving the corresponding amide intermediate **9**. This allows access to indole analogue **10**, an unusual seven-membered cyclic imine fused with a δ -lactam with two stereogenic centers.




(B) C2 Activation:

Zhang and co-workers¹¹ reported the synthesis of *N*-(6-(indol-2-yl)pyridine-3-sulfonamide) **13** starting from the substituted indole **11**. The mechanism involves the boronic acid intermediate **12**.




(C) C3 Reactivity:

In 2014, McLaughlin's group¹² published the synthesis of the violacein scaffold **17**, a microbial pigment with antimicrobial and anti-cancer activities. Indole derivatives **14** react at the C3 position with the acyl chloride derivative **15** to afford the main product **16**, key in the construction of violacein analogues **17**.




(D) C4 Activation:

Lanke and Prabhu reported the direct functionalization of *N*-protected indole-3-carbaldehyde derivatives **18** at the C4 position under mild conditions employing ruthenium as a catalyst and with the aldehyde functionality as the directing group.¹³ This reaction could be crucial in the synthesis of organic targets such as ergot- and related alkaloids.




(E) C5 Activation:

In 2013, Liebhold and Li reported the benzylation of tryptophan derivatives **19** at the C5 position of the indole ring using the fungal dimethylallyl transferase FgaPT2 (**20**).¹⁴ This method gives access to pharmacologically active lipophilic chain containing compounds **21** in moderate yield.



(F) C6 Reactivity:

In 2014, Shi and co-workers developed a Brønsted acid organocatalyzed arylation of 3-indolylmethanol derivatives **22**, affording a direct method for C6 functionalization of substituted indoles **23**, leading to scaffolds **24**.¹⁵



References

- Bandini, M.; Eichholzer, A. *Angew. Chem. Int. Ed.* **2009**, *48*, 9608.
- Kaushik, N. K.; Kaushik, N.; Attri, P.; Kumar, N.; Kim, C. H.; Verma, A. K.; Choi, E. H. *Molecules* **2013**, *18*, 6620.
- Zhang, M.-Z.; Chen, Q.; Yang, G.-F. *Eur. J. Med. Chem.* **2015**, *89*, 421.
- (a) Singla, R.; Singh, V.; Negi, A. *Adv. J. Pharm. Life sci. Res.* **2013**, *1*, 7. (b) Kumar, N. M.; Kumar, D. *Chem. Biol.* **2013**, *3*, 276.
- Blaising, J.; Polyak, S. J.; Pécheur, E.-I. *Antiviral Res.* **2014**, *107*, 84.
- (a) Yang, Y.; Jia, H.-M.; Liu, B.-L. *Molecules* **2012**, *17*, 4252. (b) Yang, Y.; Cui, M. *Eur. J. Med. Chem.* **2014**, *87*, 703.
- Yu, J.; Luo, J.; Chen, Q.; He, K.; Meng, F.; Deng, X.; Wang, Y.; Tan, H.; Jiang, H.; Zhu, W. *Tetrahedron* **2014**, *70*, 1246.
- Taber, D. F.; Tirunahari, P. K. *Tetrahedron* **2011**, *67*, 7195.
- (a) Fischer, E.; Jourdan, F. *Ber. Dtsch. Chem. Ges.* **1883**, *16*, 2241. (b) *Strategic Applications of Named Reactions in Organic Synthesis*; Kürti, L.; Czako, B., Eds.; Elsevier Academic Press: Amsterdam, **2005**.
- Lv, Z.; Li, Z.; Liang, G. *Org. Lett.* **2014**, *16*, 1653.
- Zhang, N.; Zhang, X.; Zhu, J.; Turpoff, A.; Chen, G.; Morrill, C.; Huang, S.; Lennox, W.; Kakarla, R.; Liu, R.; Li, C.; Ren, H.; Almstead, N.; Venkatraman, S.; Njoroge, F. G.; Gu, Z.; Clausen, V.; Graci, J.; Jung, S. P.; Zheng, Y.; Colacino, J. M.; Lahser, F.; Sheedy, J.; Mollin, A.; Weetall, M.; Nomeir, A.; Karp, G. M. *J. Med. Chem.* **2014**, *57*, 2121.
- McLaughlin, E. C.; Norman, M. W.; Ko, T. K.; Stolt, I. *Tetrahedron Lett.* **2014**, *55*, 2609.
- Lanke, V.; Prabhu, K. R. *Org. Lett.* **2013**, *15*, 6262.
- Liebhold, M.; Li, S.-M. *Org. Lett.* **2013**, *15*, 5834.
- Zhou, L.-J.; Zhang, Y.-C.; Zhao, J.-J.; Shi, F.; Tu, S.-J. *J. Org. Chem.* **2014**, *79*, 10390.